Skip to main content

Efzofitimod

Sarcoidosis Drug Pipeline Expands as Efzofitimod Nears Phase 3 Filing

Image
Sarcoidosis Drug Pipeline Expands as Efzofitimod Nears Phase 3 Filing

Las Vegas – – September 11, 2026 -- The sarcoidosis treatment market across the seven major markets is projected to expand steadily through 2036, driven by a pipeline of seven late- and mid-stage drug candidates targeting a disease that affects an estimated 150,000 to 200,000 patients annually in the United States alone, according to a new market report from DelveInsight.